Actively Recruiting
Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
Led by Dr. Md. Alimur Reza · Updated on 2025-07-11
160
Participants Needed
2
Research Sites
40 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.
CONDITIONS
Official Title
Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged between 18 to 65 years
- Acute illness lasting 7 days or less with symptoms such as fever over 38.0 6C, shortness of breath, new or increased cough, or chest pain
- Radiographically confirmed bacterial pneumonia showing unilateral lobar infiltrates, diffuse opacities, or alveoli filled with inflammatory fluid
You will not qualify if you...
- Severe pneumonia based on clinical and radiological assessment
- Suspected viral pneumonia or other types like nosocomial or aspiration pneumonia
- Known allergy or intolerance to study drugs
- Antibiotic use within 48 hours before study admission
- Hospitalization within the last 28 days
- Pregnancy or lactation
- Renal impairment with eGFR less than 30 mL/min
- Significant liver impairment with ALT more than three times the normal limit
- Serious immune system diseases such as AIDS or cancer
- Use of steroids at doses of 20 mg prednisolone daily or equivalent
- Receiving or planning chemotherapy or anti-cancer therapy within six months
- History of epilepsy, stroke, central nervous system disorders, or uncontrolled psychiatric illness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Popular Medical College & Hospital
Dhaka, Dhaka Division, Bangladesh, 1205
Actively Recruiting
2
Shaheed Suhrawardy Medical College & Hospital
Dhaka, Dhaka Division, Bangladesh, 1205
Actively Recruiting
Research Team
P
Prof. Khan Abul Kalam Azad, MBBS, FCPS, MD(Med), FACP(USA)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here